An industry-focused review outlined practical steps to advance in vivo CAR approaches from concept to clinical translation and highlighted commercial reagent solutions aimed at de‑risking the pipeline. The piece explained how delivering CAR‑encoding DNA or mRNA directly to T cells requires precise targeting, high editing efficiency, and robust QC for mRNA and gene‑editing tools. ACROBiosystems described labeled/unlabeled CAR‑target proteins, flow‑cytometry panels and high‑fidelity Cas nucleases as part of an interconnected quality framework to accelerate lead screening, functional assays and vector construction. The discussion emphasized assay standardization for evaluating expression, phenotype and off‑target effects in living models. For sponsors pursuing in vivo CAR therapeutics, the roadmap signals a shift toward integrated reagent-tooling and more stringent preclinical QC to meet regulatory expectations for on‑target specificity and safety.